Vaccination in the Time of COVID-19: Overcoming the Growing Threat of Vaccine-Preventable Diseases
Part 3 - Improving Vaccination Rates for Vaccine Preventable Diseases: Overcoming the Challenges of Hesitancy

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE).
This educational activity is supported by an educational grant from GlaxoSmithKline.

FACULTY

Stacey Schneider, PharmD
Adjunct Professor of Clinical Psychopharmacology
Saybrook University
Pasadena, CA

FINANCIAL DISCLOSURES

Stacey Schneider, PharmD has no actual or potential conflicts of interest in relation to this program.

The clinical reviewer, Darrell Hulisz, RPh, PharmD, has no actual or potential conflicts of interest in relation to this program.

Susanne Batesko, RN, BSN, Robin Carrino, and Bart Ecker, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENT

PHARMACY
acpe Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0430-0000-22-144-H06-P
Credits: 1.0 hours (0.10 ceu)
Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes

Published:

December 15, 2022

Expires:

December 15, 2023

TARGET AUDIENCE

This accredited activity has been designed for pharmacists.

HOW TO EARN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

The goal of this educational activity is to educate pharmacists about the importance of reversing declining vaccination rates for vaccine-preventable diseases during the ongoing COVID-19 pandemic.

LEARNING OBJECTIVES 

At the conclusion of the activity, the learner will be better able to:

  • Discuss the factors that contribute to vaccine hesitancy in the ongoing pandemic.
  • Explain the scientific evidence to alleviate mistrust in vaccinations.
  • Identify strategies and communication techniques for improving vaccination rates for vaccine-preventable diseases.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Gilead Sciences, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.